The phosphatidylinositol 3' kinase (PI3K) pathway is involved in many cellular processes including cell proliferation, survival, and glucose transport, and is implicated in various disease states such as cancer and diabetes. Though there have been numerous studies dissecting the role of PI3K signaling in different cell types and disease models, the mechanism by which PI3K signaling regulates embryonic stem (ES) cell fate remains unclear. It is believed that in addition to proliferation and tumorigenicity, PI3K activity might also be important for self-renewal of ES cells. Paling et al. (2004) reported that the inhibition of PI3K led to a reduction in the ability of leukemia inhibitory factor (LIF) to maintain self-renewal causing cells to differentiate. Studies in our lab have revealed that ES cells completely lacking GSK-3 remain undifferentiated compared to wildtype ES cells. GSK-3 is negatively regulated by PI3K suggesting that PI3K may play a vital role in maintaining pluripotency in ES cells through GSK-3. By using a modified Flp recombinase system, we expressed activated alleles of PDK-1 and PKB to create stable, isogenic ES cell lines to further study the role of the PI3K signaling pathway in stem cell fate determination. In vitro characterization of the transgenic cell lines revealed a strong tendency towards maintenance of pluripotency, and this phenotype was found to be independent of canonical Wnt signal transduction. To assess growth and differentiation capacity in vivo, the ES cell lines were grown as subcutaneous teratomas. The constitutively active PDK-1 and PKB ES cell lines were able to form all three germ layers when grown in this manner – in contrast to ES cells engineered to lack GSK-3. The resulting PI3K pathway activated cells exhibited a higher growth rate which resulted in large teratomas. In summary, PI3K signaling is sufficient to maintain self-renewal and survival of stem cells. Since this pathway is frequently mutationally activated in cancers, its effect on suppressing differentiation may contribute to its oncogenicity.

No description available.

Le système de différenciation entre le « soi » et le « non-soi » des vertébrés permet la détection et le rejet de pathogènes et de cellules allogéniques. Il requiert la surveillance de petits peptides présentés à la surface cellulaire par les molécules du complexe majeur d’histocompatibilité de classe I (CMH I). Les molécules du CMH I sont des hétérodimères composés par une chaîne lourde encodée par des gènes du CMH et une chaîne légère encodée par le gène β2-microglobuline. L’ensemble des peptides est appelé l’immunopeptidome du CMH I. Nous avons utilisé des approches en biologie de systèmes pour définir la composition et l’origine cellulaire de l’immunopeptidome du CMH I présenté par des cellules B lymphoblastoïdes dérivés de deux pairs de fratries avec un CMH I identique. Nous avons découvert que l’immunopeptidome du CMH I est spécifique à l’individu et au type cellulaire, qu’il dérive préférentiellement de transcrits abondants, est enrichi en transcrits possédant d’éléments de reconnaissance par les petits ARNs, mais qu’il ne montre aucun biais ni vers les régions génétiques invariables ni vers les régions polymorphiques. Nous avons également développé une nouvelle méthode qui combine la spectrométrie de masse, le séquençage de nouvelle génération et la bioinformatique pour l’identification à grand échelle de peptides du CMH I, dont ceux résultants de polymorphismes nucléotidiques simples non-synonymes (PNS-ns), appelés antigènes mineurs d’histocompatibilité (AMHs), qui sont les cibles de réponses allo-immunitaires. La comparaison de l’origine génomique de l’immunopeptidome de soeurs avec un CMH I identique a révélé que 0,5% des PNS-ns étaient représentés dans l’immunopeptidome et que 0,3% des peptides du CMH I seraient immunogéniques envers une des deux soeurs. En résumé, nous avons découvert des nouveaux facteurs qui modèlent l’immunopeptidome du CMH I et nous présentons une nouvelle stratégie pour l’indentification de ces peptides, laquelle pourrait accélérer énormément le développement d’immunothérapies ciblant les AMHs. / The self/nonself discrimination system of vertebrates allows detection and rejection of pathogens and allogeneic cells. It requires the surveillance of short peptides presented by major histocompatibility class I (MHC I) molecules on the cell surface. MHC I molecules are heterodimers that consist of a heavy chain produced by MHC genes and a light chain encoded by the β2-microglobulin gene. The peptides presented by MHC I molecules are collectively referred to as the MHC I immunopeptidome. We employed systems biology approaches to define the composition and cellular origin of the self MHC I immunopeptidome presented by B lymphoblastoid cells derived from two pairs of MHC-identical siblings. We found that the MHC I immunopeptidome is subject- and cell-specific, derives preferentially from abundant transcripts, is enriched in transcripts bearing microRNA response elements and shows no bias toward invariant vs. polymorphic genomic sequences. We also developed a novel personalized approach combining mass-spectrometry, next-generation sequencing and bioinformatics for high-throughput identification of MHC I peptides including those caused by nonsynonymous single nucleotide polymorphisms (ns-SNPs), termed minor histocompatibility antigens (MiHAs), which are the targets of allo-immune responses. Comparison of the genomic landscape of the immunopeptidome of MHC-identical siblings revealed that 0.5% of ns-SNPs were represented in the immunopeptidome and that 0.3% of the MHC I-peptide repertoire would be immunogenic for one of the siblings. We discovered new factors that shape the self MHC I immunopeptidome and present a novel strategy for the identification of MHC I-associated peptides that could greatly accelerate the development of MiHA-targeted immunotherapy.

Japanese encephalitis virus (JEV) causes viral encephalitis in new born and young adults that is prevalent in different parts of India and other parts of South East Asia with an estimated 6000 deaths per year. JEV is a single stranded RNA virus that belongs to the Flavivirusgenus of the family Flaviviridae. It is a neurotropic virus which infects the central nervous system (CNS). The virus follows a zoonotic life-cycle involving mosquitoes and vertebrates, chiefly pigs and ardeid birds, as amplifying hosts. Humans are dead end hosts. After entry into the host following a mosquito bite, JEV infection leads to acute peripheral leukocytosis in the brain and damage to Blood Brain Barrier (BBB). The exact role of the endothelial cells during CNS infection is still unclear. However, disruption of this endothelial barrier has been shown to be an important step in entry of the virus into the brain. Humoral and cell mediated immune responses during JEV infection have been intensively investigated. Previous studies from our lab have shown the activation of cytotoxic T-cells (CTLs) upon JEV infection. MHC molecules play pivotal role in eliciting both adaptive (T-cells) and innate (NK cells) immune response against viral invasion. Many viruses such as HIV, MCMV, HCMV, AdV and EBV have been found to decrease MHC expression upon infection. On the contrary, flaviviruses like West Nile Virus (WNV) have been found to increase MHC-I and MHC-II expression. More recently, data from our lab has shown that JEV infection can lead to upregulation of mouse non-classical MHC class Ib molecules like Qb1, Qa1 and T-10 along with classical MHC molecules. Non-classical MHC molecules are important components of the innate and adaptive immune systems. Non-classical MHC molecules differ from their classical MHC class I counterparts by their limited polymorphism, restricted tissue distribution and lower levels of cell surface expression. Human classical MHC class I molecules are HLA-A, -B and –C while non-classical MHC Class Ib molecules are HLA-E, -G and –F. HLA-E, the human homologue of the mouse non-classical MHC molecule, Qa-1b has been shown to be the ligand for the inhibitory NK, NKG2A/CD94 and may bridge innate and adaptive immune responses. In this thesis, we have studied the expression of human classical class I molecules HLA-A, -B, -C and the non-classical HLA molecule, HLA-E in immortalized human brain microvascular endothelial cells (HBMEC), human endothelial like cell line ECV304 (ECV), human glioblastoma cell line U87MG and human foreskin fibroblast cells (HFF). We observed an upregulation of classical HLA molecules and HLA-E mRNA in endothelial and fibroblast cells upon JEV infection. This mRNA increase also resulted in upregulation of cell surface classical HLA molecules and HLA-E in HFF cells but not in both the human endothelial cell lines, ECV and HBMECs. Release of soluble classical HLA molecules upon cytokine treatment has been a long known phenomenon. Recently HLA-E has also been shown to be released as a 37 kDa protein from endothelial cells upon cytokine treatments. Our study suggests that JEV mediated upregulation of classical HLA and HLA-E upregulation leads to release of both Classical HLA molecules and HLA-E as soluble forms in the human endothelial cell lines, ECV and HBMEC. This shedding of sHLA-E from human endothelial cells was found to be mediated by matrix metalloproteinase (MMP) proteolytic activity. MMP-9, a protease implicated in release of sHLA molecules was also found to be upregulated upon JEV infection only in endothelial cell lines but not in HFF cells. Our study provides evidence that the JEV mediated solubilisation of HLA-E could be mediated by MMP-9. Further, we have tried to understand the role of the MAPK pathway and NF-κB pathway in the process of HLA-E solubilisation by using specific inhibitors of these pathways during JEV infection of ECV cells. Our data suggests that release of sHLA-E is dependent on p38 and JNK pathways while ERK 1/2 and NF-κB pathway only had a minor role to play in this process. Treatment of endothelial cells with TNF-α, IL-1β and IFN-γ is known to result in release of sHLA-E. In addition to TNF-α and IFNtreatment, we observed that activating agents like poly (I:C), LPS and PMA also resulted in the shedding of sHLA-E from ECV as well as U87MG but not from HFF cells. Treatment of endothelial cells with IFN-β, a type-I interferon also led to release of sHLA-E. IFN-γ, a type II interferon and TNF-α are known to show additive increase in solubilisation of HLA-E. We studied the interaction between type I interferon, IFN-β and TNF-α with regard to shedding of sHLA- E. Both IFNand TNF, when present together caused an additive increase in the shedding of sHLA-E. These two cytokines were also found to potentiate the HLA-E and MMP-9 mRNA expression. Hence, our data suggest that these two cytokines could be working conjunctly to release HLA-E, when these two cytokines are present together as in the case of virus infection of endothelial cells. HLA-E is known to be a ligand for NKG2A/CD94 inhibitory receptors present on NK and a subset of T cells. Previous reports have suggested that NKG2A/CD94 mediated signaling events could inhibit ERK 1/2 phosphorylation leading to inhibition of NK cell activation. IL-2 mediated ERK 1/2 phosphorylation is known to play a very important role in maintenance and activation of NK cells. We studied the effects of sHLA-E that was released, either by JEV infection or IFN-γ treatment on IL-2 mediated ERK 1/2 phosphorylation in two NK cell lines, Nishi and NKL. The soluble HLA-E that was released upon JEV infection was functionally active since it inhibited IL-2 and PMA induced phosphorylation of ERK 1/2 in NKL and Nishi cells. Virus infected or IFN-γ treated ECV cell culture supernatants containing sHLA-E was also found to partially inhibit IL-2 mediated induction of CD25 molecules on NKL cells. CD25 is a component of the high affinity IL-2 receptor and hence could play an important role in proliferation and activation of NK cells. sHLA-E was also found to inhibit IL-2 induced [3H]-thymidine incorporation suggesting that, similar to cell surface expressed HLA-E, sHLA-E could also inhibit the proliferation and activation of NK cells. In summary, we found that establishment of JEV infection and production of cytokines like IFN-β, TNF-α, IL-6 along with MMP-9 in human endothelial cells. These cytokines may also indirectly lead to the reported damage and leukocyte infiltration across infected and uninfected vicinal endothelial cells. The increased surface expression of HLA-E in fibroblast and release of sHLA and sHLA-E molecules from endothelial cells may have an important immunoregulatory role. HLA-E is an inhibitory ligand for NKG2A/CD94 positive CD8+ T and NK cells. Hence our finding that sHLA-E can inhibit NK cell proliferation suggests an immune evasive strategy by JEV.

Linhagens celulares humanas têm atraído grande interesse devido a sua capacidade de glicosilar proteínas de maneira mais semelhante às proteínas nativas humanas, reduzindo o potencial de respostas imunológicas contra epítopos não humanos. No entanto, por se tratar de uma aplicação recente, essas células ainda não foram extensamente caracterizadas e cultivadas em condições reprodutíveis da escala industrial, ou seja, em suspensão e em meios de cultura livres de soro fetal bovino (SFB). Em função disso, o objetivo principal deste trabalho foi estabelecer culturas livres de SFB e em suspensão para as linhagens celulares humanas SK-Hep-1, HepG2 e HKB-11, que têm despertado grande interesse devido ao potencial de produção de proteínas recombinantes. Para isso, quatro formulações comerciais livres de SFB foram avaliadas. As células que apresentaram bons resultados na adaptação aos meios realizada em garrafas estáticas foram então adaptadas para crescimento em suspensão. Foi possível realizar a adaptação satisfatória da célula HKB-11 ao meio FreeStyle e da célula SK-Hep-1 ao meio SFMII bem como a criopreservação das mesmas também em condições livres de SFB. A caracterização cinética das células adaptadas mostrou que a célula HKB-11 apresentou concentração celular quatro vezes superior a da célula SK-Hep-1 (8,6x106 e 1,9x106 células/mL, respectivamente) e apresentou crescimento celular durante 18 dias em cultura. A velocidade específica de crescimento máxima (?max) foi semelhante nas duas células (0,0159 h-1 para a HKB-11 e 0,0186 h-1 para SK-Hep-1). A limitação do crescimento das células adaptadas não parece estar associada à exaustão de glicose e glutamina, tampouco à formação de lactato em concentrações inibitórias. Todavia, para ambos os casos, foi observada produção de amônia em concentrações consideradas inibitórias (2 - 5 mM). De maneira geral, foi possível estabelecer culturas celulares em condições compatíveis com o desenvolvimento de um bioprocesso reprodutível, seguro e em concordância com as boas práticas de fabricação. / Human cell lines have attracted great interest since they are capable of producing glycosylated proteins in a more similar way to native human proteins, reducing the potential for immune responses against non-human epitopes. However, these human cell lines have not been extensively characterized and cultured in large scale and in serum-free suspension conditions. As a result, the main objective of this work was to adapt three human cell lines: SK-Hep-1, HepG2 and HKB-11 to serum-free suspension cultures, since they are promising systems of recombinant protein expression. For this task, four commercial serum-free media were tested. Adapted cell lines in T-flasks were further adapted to suspension cultures. Results showed that both HKB-11 and SK-Hep-1 were adapted to serum-free suspension cultures in FreeStyle and SFMII, respectively and were cryopreservated in serum-free formulations. Kinetic characterization showed that HKB-11 cell concentration was four times higher than SK-Hep-1 cell (8,6x106 and 1,9x106 cells/ml, respectively) and showed cell growth in culture over 18 days. The maximum specific growth rate (?max) was similar for both cell lines (0,0159 h-1 to HKB-11 and 0,0186h-1 to SK-Hep-1). Growth limitation of adapted human cell lines does not seem to be associated with depletion of glucose and glutamine, nor with the formation of lactate in inhibitory concentrations. However, in both cases, ammonia production achieved inhibitory concentrations (2 - 5 mM). In general, it was possible to establish human cell cultures that are compatible with reproducible and safe bioprocess conditions and in compliance with good manufacturing practices.

O desenvolvimento e invasão de tumores cerebrais primários são diretamente influenciados pela matriz extracelular. Considerando que lisil oxidase (LOX) e os demais membros da família das lisil oxidases (LOXL1, LOXL2, LOXL3 e LOXL4) apresentam complexidade tanto estrutural quanto funcional e estão envolvidos em processos biológicos vitais, como motilidade celular, sinalização celular e regulação gênica, a desregulação da expressão destas proteínas pode levar à gênese e progressão tumoral. O presente trabalho teve como objetivos avaliar os níveis de expressão dos genes que codificam todos os membros da família das lisil oxidases em astrocitomas de diferentes graus de malignidade e correlacionar com a expressão de BMP1 e HIF1A, mutação de IDH1 e tempo de sobrevida total dos pacientes. Adicionalmente, as expressões das proteínas codificadas por estes genes foram também realizadas, além de um estudo funcional in vitro do papel de LOX em astrocitomas. A análise da expressão dos genes foi realizada por PCR quantitativa em tempo real numa série de 153 astrocitomas e 22 amostras de tecido cerebral não neoplásico. A expressão proteica foi conduzida por imuno-histoquímica em amostras de astrocitomas. O silenciamento da expressão de LOX foi realizado em linhagens celulares de glioblastoma humano U87MG e A172 transfectadas com o siRNA para os ensaios funcionais. A expressão de todos os genes (LOX, LOXL1, LOXL2, LOXL3, LOXL4, BMP1 e HIF1A) aumentou com o grau de malignidade dos astrocitomas, com maiores níveis nos casos de glioblastoma. Foi encontrada uma correlação positiva nos valores de expressão dos genes principalmente nos glioblastomas. Somente a expressão de LOXL3 teve um impacto na sobrevida dos casos com GBM. Pacientes com maior expressão apresentaram maior sobrevida em relação aos com menor expressão de LOXL3. Os casos de astrocitoma grau II com mutação de IDH1 apresentaram menor expressão de LOXL1 e de LOXL4 quando comparados com os casos sem mutação. Os casos de GBM com mutação de IDH1, por sua vez, apresentaram menores níveis de expressão de LOX e de LOXL1 do que os casos sem IDH1 mutado. Os níveis de expressão das proteínas da família das lisil oxidases também estavam maiores nas amostras de glioblastoma, com localização nuclear e citoplamastica das células, além de marcação do endotélio. Interessantemente, um caso de glioblastoma com mutação de IDH1 apresentou menor expressão de LOX, inclusive nas células endoteliais. Nas análises funcionais, o silenciamento de LOX por siRNA e o tratamento com o inibidor BAPN das linhagens celulares U87MG e A172 afetaram a capacidade de migração. Além sito, a menor expressão de LOX afetou a capacidade de invasão e crescimento independente de ancoragem das células. Em conjunto, esses resultados corroboram o papel de LOX em processo importantes da tumorigênese dos astrocitomas. Adicionalmente, a expressão de LOX é influenciada pelo status de mutação de IDH1. Portanto, este trabalho fornece novas informações para as possíveis intervenções terapêuticas para o tratamento dos pacientes com astrocitomas / The development and invasion of primary brain tumors are directly influenced by the extracellular matrix. Considering that lysyl oxidase (LOX) and other lysyl oxidase family members (LOXL1, LOXL2, LOXL3 e LOXL4) have both structural and functional complexity and that they are involved in vital biological processes such as cell motility, cell signaling and gene regulation, a deregulation of these proteins can lead to the genesis and tumor progression. This study aimed to evaluate the expression levels of genes that code for the lysyl oxidase family members in astrocytomas of different malignant grades and to correlate to the expression of BMP1 and HIF1A, IDH1 mutation and overall patients\' survival. Moreover, protein expression coded by these genes was also analyzed, besides an in vitro functional study of LOX role in astrocytomas. Gene expression analysis was performed by quantitative real-time PCR in a series of 153 astrocytomas and 22 samples of non-neoplastic brain. Protein expression was analyzed by immunohistochemistry in astrocytoma samples. LOX knockdown was performed in cells of human glioblastoma U87MG and A172 transfected with siRNA. Expression levels of all genes (LOX, LOXL1, LOXL2, LOXL3, LOXL4, BMP1 e HIF1A) increased with the malignant grade of astrocytomas, glioblastomas presenting the higher levels. Positive correlations of gene expression values were observed specially in glioblastomas. Only LOXL3 expression impacted in the overall survival of glioblastoma cases. Patients with higher expression presented longer survival time than those with lower LOXL3 expression. Astrocytoma grade II cases with IDH1 mutation presented lower LOXL1 and LOXL4 expression when compared to those cases with wild type IDH1. On the other hand, GBM cases with IDH1-mutated presented lower LOX and LOXL1 expression than GBM cases without IDH1 mutation. Protein expression levels of lysyl oxidase family members were also higher in glioblastoma samples, with both nuclear and cytoplasmic localization, and also endothelium staining. Interestingly, a glioblastoma case with IDH1-mutated had lower LOX expression, including endothelial cells. For functional analysis, LOX knockdown by siRNA and treatment with inhibitor BAPN of U87MG and A172 cell lines affected migration behavior. Furthermore, lower LOX expression affected invasion capacity and anchorage independent growth. Altogether, these results corroborate LOX role in important processes of astrocytoma tumorigenesis. Additionally, LOX expression is influenced by IDH1 mutational status in glioblastomas. Therefore, our work provides new insights for possible therapeutic interventions for patients with astrocytomas

A biodiversidade de plantas brasileiras é uma fonte muito rica de moléculas bioativas, dentro da proposta da busca por novas drogas antitumorais, avaliamos neste estudo o potencial antiproliferativo do composto 7-epi-clusianona. Foram utilizadas duas linhagens celulares derivadas de tumor de mama humana, Hs 578T e MCF-7, cultivadas em monocamada e como esferoides. O IC50 após 48 horas de tratamento das células é de 20 μM para Hs 578T e 6 μM para MCF-7. A análise do ciclo celular mostrou que o composto é capaz de reter as células em fase G1/G0 em ambas as linhagens em 2D, mas não em 3D. O composto é capaz de induzir as células a senescência celular, como mostrado pelo ensaio de detecção de β-galactosidase. Esses dados indicam que o composto 7-epi-clusianona é uma molécula promissora, que demonstrou potencial antitumoral em células de tumor de mama. A cultura tridimensional se mostrou mais resistente ao tratamento com 7-epi-clusianona, portanto estudos mais abrangentes são necessários para melhor entendimento dos efeitos do composto sobre esse tipo de cultura. / Brazilian flora is considered one of the most diverse in the world and natural products are some of the important sources of new antitumoral compounds. The aim of this study was to evaluate the antiproliferative potential of 7-epi-clusianone. Two cell lines derived from human breast tumor were used, Hs 578T and MCF-7, cultured in monolayer and as spheroids. The IC50 after 48 hours of treatment is 20 μM to Hs 578T cells and 6 μM to MCF-7 cells. Cell cycle analysis showed induction of cell cycle arrest in G1/S phase in cells cultured in monolayers, but not in spheroids. The amount of cells in senescence after the treatment with 7-epi-clusianone is higher than the control group, as seen by the senescence β-galactosidase staining assay. These data suggest that 7-epi-clusianone is a promising molecule against breast cancer cells. We show that 3D culture was more resistant to treatment than 2D culture, therefore more comprehensive studies are needed to better understand the effects of 7-epi-clusianone on this kind of culture.

Indiana University-Purdue University Indianapolis (IUPUI) / Juvenile Myelomonocytic Leukemia (JMML) is rare, fatal myeloproliferative disease (MPD) affecting young children, and is characterized by expansion of monocyte lineage cells and hypersensitivity to Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) stimulation. JMML is frequently associated with gain-of-function mutations in the PTPN11 gene, which encodes the protein tyrosine phosphatase, Shp2. Activating Shp2 mutations are known to promote hyperactivation of the Ras-Erk signaling pathway, but Akt is also observed to have enhanced phosphorylation, suggesting a potential role for Phosphatidylinositol-3-Kinase (PI3K)-Akt signaling in mutant Shp2-induced GM-CSF hypersensitivity and leukemogenesis. Having demonstrated that Class IA PI3K is hyperactivated in the presence of mutant Shp2 and contributes to GM-CSF hypersensitivity, I hypothesized the hematopoietic-specific Class IA PI3K catalytic subunit p110δ is a crucial mediator of mutant Shp2-induced PI3K hyperactivation and GM-CSF hypersensitivity in vitro and MPD development in vivo. I crossed gain-of-function mutant Shp2 D61Y inducible knockin mice, which develop fatal MPD, with mice expressing kinase-dead mutant p110δ D910A to evaluate p110δ’s role in mutant Shp2-induced GM-CSF hypersensitivity in vitro and MPD development in vivo. As a comparison, I also crossed Shp2 D61Y inducible knockin mice with mice bearing inducible knockout of the ubiquitously expressed Class IA PI3K catalytic subunit, p110α. I found that genetic interruption of p110δ, but not p110α, significantly reduced GM-CSF-stimulated hyperactivation of both the Ras-Erk and PI3K-Akt signaling pathways, and as a consequence, resulted in reduced GM-CSF-stimulated hyper-proliferation in vitro. Furthermore, I found that mice bearing genetic disruption of p110δ, but not p110α, in the presence of gain-of-function mutant Shp2 D61Y, had on average, smaller spleen sizes, suggesting that loss of p110δ activity reduced MPD severity in vivo. I also investigated the effects of three PI3K inhibitors with high specificity for p110δ, IC87114, GDC-0941, and GS-9820 (formerly known as CAL-120), on mutant Shp2-induced GM-CSF hypersensitivity. These inhibitors with high specificity for p110δ significantly reduced GM-CSF-stimulated hyperactivation of PI3K-Akt and Ras-Erk signaling and reduced GM-CSF-stimulated hyperproliferation in cells expressing gain-of-function Shp2 mutants. Collectively, these findings show that p110δ-dependent PI3K hyperactivation contributes to mutant Shp2-induced GM-CSF hypersensitivity and MPD development, and that p110δ represents a potential novel therapeutic target for JMML.

Cellers tillväxthastighet varierar avsevärt mellan olika celltyper. Fullt specialiserade celler delar sig sällan och fokuserar i stället på sina specifika funktioner, medan stamceller aktivt delar sig för att upprätthålla en balans av nya och gamla celler. Denna studie syftar till att odla och analysera två mänskliga blodcancercellinjer: erytroleukemiska K562-celler och L428-celler från Hodgkins lymfom. Studien fokuserar på de två cellinjernas olika tillväxthastighet samt transkriptionsaktivitet under olika förhållanden och behandlingar. Projektet inkluderar även att ta fram ett helt nytt, effektiviserat protokoll för extraktion och kvantifiering av DNA, nascent RNA, mRNA och protein från ett enda prov. Projektet tar också upp utmaningen att se om det finns en koppling mellan cellernas tillstånd och deras transkriptionsaktivitet, eftersom nuvarande sekvenseringsnormaliseringstekniker gör att de totala nivåerna av transkription inte blir jämförbara mellan olika cellinjer. Genom att kvantifiera cellernas tillväxthastighet och transkriptionsaktivitet identifierades en potentiell koppling mellan högre tillväxthastighet och ökad mängd RNA-produktion, vilket tyder på ett samband som ser till att tillräckligt stor mängd cellkomponenter produceras för dottercellerna. Dessutom syftar studien till att undersöka de två cellinjernas respons på behandling med differentieringsinducerande hemin, känt för att inducera erytroid differentiering hos myeloida celler såsom K562-cellinjen. Trots deras olika hematopoetiska ursprung visade sig både K562- och L428-cellinjerna reagera på behandlingen och utvecklas mot röda blodkroppar. Detta kan påvisas genom att hemin gör att deras respektive tillväxthastigheter påverkas på samma sätt, samt att cellerna får en djupröd färg, vilket indikerar produktion av hemoglobin och är ett välkänt tecken på erytroid differentiering. / Cell proliferation rates vary significantly among different cell types. Terminally differentiated cells rarely divide, focusing on their specialized functions, while stem cells actively proliferate to maintain tissue homeostasis. This study aims to culture and analyze two human blood cancer cell lines: erythroleukemia K562 cells and Hodgkin's lymphoma L428 cells. The investigation focuses on their proliferation rates and transcriptional activities under various conditions and treatments. The project also includes the establishment of a novel, streamline protocol for extracting and quantifying DNA, nascent RNA, mRNA and protein from one single sample. The study also addresses the challenge of correlating cell state with transcriptional activity, noting that current sequencing normalization techniques renders total levels of transcription incomparable between cell lines. By quantifying proliferation rates and transcriptional activity, a potential connection between proliferation rate and transcriptional activity was found. Higher proliferation rate corresponded to samples with larger amounts of RNA and higher transcription of nascent RNA, indicating an association that facilitates the production of sufficient cellular components necessary for the two daughter cells.  Additionally, the study investigates the two cell lines’ responsiveness to differentiation-inducing hemin, known to induce differentiation toward the erythrocyte lineage for myeloid cells such as the K562 cell line. The findings from this study show that, despite belonging to different parts of the hematopoietic lineage, both the K562 cells and the L428 cells are responsive to hemin-induced differentiation toward the erythrocyte lineage. This is demonstrated by the fact that their proliferation rates are equally affected upon hemin treatments, and because both K562 and L428 cells turn red as a reflection of the induced production of hemoglobin, which is a recognized effect of hemin-induced erythrocytic differentiation.

No description available.